Climb Bio (CLYM) announced the upcoming presentation of CLYM116 preclinical data and published budoprutug pMN Phase 1b long-term outcome data at the 2025 American Society of Nephrology Kidney Week, ...

Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK ...

B cell development in swine presents a unique model within mammalian immunology. In contrast to traditional murine and human systems, swine exhibit notable differences in the temporal order of heavy ...

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile ...

A novel drug for systemic lupus erythematosus (SLE) first developed in China, and approved there since 2021, did well enough in a new placebo-controlled phase III trial that approval in Western ...

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...

Project Title: Assessing the Role of SHP2 on B Cell Proliferation in a Lupus Mouse Model Project Summary: Lupus is a disease affecting 1.5 million Americans. While the exact causes of lupus are ...